Synthetic Biology, according to its proponents, is moving at five times the pace of Moore’s law – basically doubling its capabilities and halving its costs every four months. Except that brash billionaire Craig Venter, often dubbed Bioscience’s Bad Boy, is no Gordon Moore. Venter has just announced that his team has produced Synthia 3.0 – the simplest human-made and self-replicating lifeform ever. Synthia 1.0 was announced – after years of delays – in 2010 and its second coming in this new form has been awaited ever since. Synthia 2.0 slipped by without notice – apparently not much to talk about – but this new version is being hailed by at least some synthetic biology scientists as a breakthrough.
Genomics & Biotechnology
ETC Group has tracked developments in the genetic engineering of plants, animals and microorganisms since the early 1980s and tracked the transition of the biotechnology industry into a broader 'life sciences' industry spanning agriculture, pharmaceuticals, energy and chemicals production. Today, biotechnology encompasses a variety of techniques that involve the use and manipulation of living organisms to make commercial products (including cell and tissue culture, recombinant DNA technology and synthetic biology). Underlying the commercial manipulation of life are ever more powerful genomics technologies (gene-mapping) that enable companies to quickly 'read,' store and digitally analyze genetic information -- either of single organisms or entire ecosystems (known as metagenomics). ETC Group (then RAFI) was one of the first organizations to warn of the downside of genetic engineering of crops and livestock and has since kept an eye on developments in human biotech, synthetic biology, biowarfare and industrial biotech.